Alpelisib (NVP-BYL719, Piqray, Table 4) is an oral PI3Kα selective inhibitor that was approved by FDA in 2019 for PIK3CA-mutated, HR+/HER2− advanced BC in combination with fulvestrant [195]. The gene discussed is HR; the disease is breast cancer.